Abstract
Introduction: The mechanistic definition of chronic pancreatitis (CP) identifies acute pancreatitis (AP) as a precursor stage. We hypothesized that clinical AP frequently precedes the diagnosis of CP and is associated with patient- and disease-related factors. We describe the prevalence, temporal relationship and associations of AP in a well-defined North American cohort. Methods: We evaluated data from 883 patients with CP prospectively enrolled in the North American Pancreatitis Studies across 27 US centers between 2000 and 2014. We determined how often patients had one or more episodes of AP and its occurrence in relationship to the diagnosis of CP. We used multivariable logistic regression to determine associations for prior AP. Results: There were 624/883 (70.7%) patients with prior AP, among whom 161 (25.8%) had AP within 2 years, 115 (18.4%) within 3–5 years, and 348 (55.8%) >5 years prior to CP diagnosis. Among 504 AP patients with available information, 436 (86.5%) had >1 episode. On multivariable analyses, factors associated with increased odds of having prior AP were a younger age at CP diagnosis, white race, abdominal pain, pseudocyst(s) and pancreatic duct dilatation/stricture, while factors associated with a lower odds of having prior AP were exocrine insufficiency and pancreatic atrophy. When compared with patients with 1 episode, those with >1 AP episode were diagnosed with CP an average of 5 years earlier. Conclusions: Nearly three-quarters of patients were diagnosed with AP prior to CP diagnosis. Identifying which AP patients are at-risk for future progression to CP may provide opportunities for primary and secondary prevention.
Original language | English |
---|---|
Pages (from-to) | 1091-1098 |
Number of pages | 8 |
Journal | Pancreatology |
Volume | 22 |
Issue number | 8 |
DOIs | |
State | Published - Dec 1 2022 |
Bibliographical note
Publisher Copyright:© 2022
Funding
Research reported in this publication was supported by the National Cancer Institute (NCI) and National Institute of Diabetes And Digestive and Kidney Diseases (NIDDK) under award numbers: DK061451 (DCW), DK077906 (DY), U01DK108306 (DY), U01 DK127377 (DY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.V.K.S. is a consultant for AbbVie, Vertex, and Ariel Precision Medicine; scientific advisory board member and equity holder in Kyttaro; and receives grant support from AbbVie. D.C.W is co-founder and Chief Scientific Officer of Ariel Precision Medicine and may have equity. Research reported in this publication was supported by the National Cancer Institute ( NCI ) and National Institute of Diabetes And Digestive and Kidney Diseases ( NIDDK ) under award numbers: DK061451 (DCW), DK077906 (DY), U01DK108306 (DY), U01 DK127377 (DY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funders | Funder number |
---|---|
National Institutes of Health (NIH) | |
National Childhood Cancer Registry – National Cancer Institute | |
National Institute of Diabetes and Digestive and Kidney Diseases | U01DK108306, R01DK061451, DK077906, U01 DK127377 |
National Institute of Diabetes and Digestive and Kidney Diseases | |
AbbVie |
Keywords
- Alcohol
- Natural history
- Pancreatitis
- Prevention
- Treatment
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology